Compare Abeona Therapeutics Inc (ABEO) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Wynn Resorts, Limited — how do they compare? Abeona Therapeutics Inc trades at $7.51 (market cap $421.19M), while Wynn Resorts, Limited trades at $103.46 (market cap $10.79B). The key difference: Wynn Resorts, Limited is far larger — about 25.6× Abeona Therapeutics Inc's market cap, and Wynn Resorts, Limited pays a 0.95% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | WYNN | |
|---|---|---|
Market Cap | $421.19M | $10.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $133.34 |
52-Week Low | $4.17 | $94.37 |
Enterprise Value | $276.10M | $21.03B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
Wynn Resorts (WYNN) trades at $104.59, up 2.04% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations, driven by Macau performance, though U.S. margins face pressure. The company maintains solid revenue growth but carries high debt levels, with net cash flow negative due to significant capital expenditures for expansion projects like Wynn Al Marjan.
The outlook is cautiously optimistic, with a consensus price target of $133 offering ~27% upside. Key opportunities include Macau recovery and new project growth, while risks involve high leverage, rising capex, and regional economic sensitivity. Investors should weigh strong institutional support against execution risks in upcoming expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
